



INDO US
BIO-TECH LIMITED
(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Date: 11th February, 2025

BSE Limited

Dept. of Corporate Services,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

BSE Scrip Code - 541304

National Stock Exchange of India Limited

Dept. of Corporate Compliances,
Exchange Plaza, C-1 Block-G,
Bandra Kurla Complex,
Bandra (E) Mumbai- 400 051

NSE Symbol: INDOUS

Sub: Outcome of Board Meeting held on 11th February, 2025, pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Ref: Indo Us Bio Tech Limited

Dear Sir,

Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held on Tuesday, 11th February, 2025 at the registered office of the Company situated at 309, Shanti Mall, Satadhar Char Rasta, Opp. Navrang Tower, Sola Road, Ahmedabad, Gujarat, 380061 have considered and approved the following items of business:

1. The Board approved unaudited financial results of the company for the quarter ended 31st December, 2024 along with limited review reports obtained from the Auditor of the Company.

The Board Meeting commenced at 14.00 P.M. and concluded at 14:20 P.M.

You are requested to kindly take the same on record.

Thanking you,

For, Indo us Bio Tech Limited

DIMPY
DIVYANGBHAI
JOSHI

Digitally signed by DIMPY
DIVYANGBHAI JOSHI
Date: 2025.02.11 14:23:53
+05'30'


Ms. Dimpy Joshi

Company Secretary & Compliance officer





INDO US
BIO-TECH LIMITED
 (AN ISO CERTIFIED COMPANY)
 CIN LO1122GJ2004PLC043550



Indo US Bio-tech Limited

CIN: LO1122GJ2004PLC043550

Registered Office : 309, Shanti Mall, Sattadhar Char Rasta, Sola Road, Ahmedabad - 380061

Statement of standalone unaudited financial results for the quarter ended on 31st December 2024

(Amount in Lakhs)

PARTICULARS	Quarter Ended			Nine months ended		Year ended 31-03-2024 (Audited)
	31-12-2024 (Unaudited)	30-09-2024 (Unaudited)	31-12-2023 (Unaudited)	31-12-2024 (Unaudited)	31-12-2023 (Unaudited)	
I	Income					
Revenue from operations	2,356.35	2,217.26	2,211.37	7,045.38	5,707.01	7,283.63
Other income	1.92	1.52	7.70	6.25	10.86	31.95
Total income from operations	2,358.27	2,218.79	2,219.07	7,051.63	5,717.87	7,315.58
II	Expenses					
Purchases	23.91	9.37	106.92	46.68	568.62	588.28
Production Expenses	1,637.34	1,113.67	1,383.15	4,013.36	3,375.01	6,896.09
Change in Inventories	(94.98)	329.53	49.87	764.47	22.58	(2,547.17)
Employee benefit expenses	22.67	24.23	29.62	75.72	97.04	117.00
Finance costs	38.40	51.56	37.34	122.95	115.47	151.00
Depreciation and amortization expenses	15.83	17.53	18.95	53.37	60.32	80.05
Other expenses	213.36	228.31	217.83	709.92	661.33	1,149.90
Total expenses	1,856.51	1,774.21	1,843.69	5,786.47	4,900.36	6,435.15
III	Profit/(Loss) before exceptional items and tax	501.76	444.58	375.39	1,265.15	880.44
IV	Exceptional items- Prior Period Items					
V	Profit/(Loss) before tax	501.76	444.58	375.39	1,265.15	880.44
VI	Tax expenses					
a) Current tax	(1.37)	0.59	9.00	-	30.00	36.94
b) Income tax prior year	1.68	(1.68)	0.39	-	25.77	25.77
b) Deferred tax	(4.02)	9.72	(2.47)	6.88	(10.97)	(7.41)
Total tax expenses	(3.71)	8.63	6.92	6.88	44.80	55.30
VII	Net Profit/(Loss) for the period/year	505.47	435.95	368.46	1,258.27	825.14
VIII	Other comprehensive income (net of tax)					
Items that will not be reclassified to profit or loss:						
i) Remeasurement of post employment benefit obligations	1.13	2.28	-	3.41	-	-
ii) Income-tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
Total other comprehensive income	1.13	2.28	-	3.41	-	-



Regd. Office :

309, Shanti Mall, Sattadhar Cross Road, Opp. Navrang Tower, Ahmedabad-380061
 © 079-27491807 © +91-9909043999

R & D farm • Processing Plant • Cold Storage
 Village - Bardoli Kothi, Indira Nagar, Near Cyphon,
 Ta. - Dehgam, Dist - Gandhinagar - 382305, Gujarat.



INDO US
BIO-TECH LIMITED
 (AN ISO CERTIFIED COMPANY)
 CIN LO1122GJ2004PLC043550



IX	Total comprehensive income for the period/year (VII+VIII)	504.34	433.67	368.46	1,254.86	772.71	825.14
X	Paid-up equity share capital (face value of Rs.10 per share)	2,005.20	2,005.20	2,005.20	2,005.20	2,005.20	2,005.20
XI	Other equity (excluding revaluation reserve)						4,446.98
XII	EPS in Rs. (Face Value of Rs.10/- each)*						
	-Basic	2.52	2.16	1.84	6.26	3.85	4.11
	-Diluted	2.52	2.16	1.84	6.26	3.85	4.11
	-Adjusted	2.52	2.16	1.84	6.26	3.85	4.11
	*not annualised						


Notes

- (1) The financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14th November 2024 and the Statutory Auditors of the Company have expressed an unmodified opinion on these results.
- (2) The company is dealing in one major product segment, i.e. Seed Cultivation, processing and trading.
- (3) The company has issued bonus share in the ratio of 1:1 as on 01st September, 2023.
- (4) Investor complained - opening unresolved -NIL, Received during the quarter 2, resolved during the quarter- 2 and balance unresolved at the end of the quarter NI
- (5) The figures have been regrouped/rearranged wherever necessary.

For, INDO US BIO-TECH LIMITED

Place: Ahmedabad
 Date: 11-02-2025

[Signature]
 DIRECTOR



FOR GAUTAM N ASSOCIATES
 CHARTERED ACCOUNTANTS

[Signature]
 GAUTAM RANDAWAT
 (Partner)

UDIN:- 25032742BJIIG18727



Regd. Office :

309, Shanti Mall, Sattadhar Cross Road, Opp. Navrang Tower, Ahmedabad-380061
 ☎ 079-27491807 ☎ +91-9909043999

R & D farm • Processing Plant • Cold Storage
 Village - Bardoli Kothi, Indira Nagar, Near Cyphon,
 Ta. - Dehgam, Dist - Gandhinagar - 382305, Gujarat.



INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND YEAR TO DATE UNAUDITED STANDLONE IND-AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED.

LIMITED REVIEW REPORT

To,
The Board of Directors,
Indo US Bio-Tech Limited,
Ahmedabad

1. We have reviewed the accompanying standalone statement of unaudited financial results of **Indo US Bio-Tech Limited** (CIN: L01122GJ2004PLC043550) (the company) for the quarter ended 31st December 2024 and year to date results for the period 1st April 2024 to 31st December 2024 ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as amended (Listing Regulations).
2. This standalone statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act., 2013 (the Act) read with relevant rules issued there under and other recognized accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review of the standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the standalone financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying standalone statement of unaudited financial results prepared in accordance with applicable accounting standards s specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules made thereunder and other accounting principles generally accepted in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gautam N Associates
Chartered Accountants
FRN: 103117W



Gautam Nandawat
Partner,
M No: 032742
UDIN: 25032742BMJJIG8727



Place: Chhatrapati Sambhajinagar
Date: 11-02-2025